Coya Therapeutics, Inc.
COYA
$6.73
$0.233.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 163.60K | 257.90K | 2.00K | -- | 3.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 163.60K | 257.90K | 2.00K | -- | 3.43M |
| Cost of Revenue | 3.66M | 5.21M | 1.94M | 2.22M | 4.57M |
| Gross Profit | -3.50M | -4.96M | -1.94M | -2.22M | -1.14M |
| SG&A Expenses | 2.91M | 2.71M | 2.14M | 2.22M | 2.09M |
| Depreciation & Amortization | 6.80K | 6.80K | 6.80K | 6.80K | 6.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.58M | 7.93M | 4.08M | 4.45M | 6.66M |
| Operating Income | -6.41M | -7.68M | -4.08M | -4.45M | -3.24M |
| Income Before Tax | -6.10M | -7.31M | -3.64M | -4.02M | -2.89M |
| Income Tax Expenses | -- | -- | -720.30K | -- | -- |
| Earnings from Continuing Operations | -6.10M | -7.31M | -2.92M | -4.02M | -2.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.10M | -7.31M | -2.92M | -4.02M | -2.89M |
| EBIT | -6.41M | -7.68M | -4.08M | -4.45M | -3.24M |
| EBITDA | -6.41M | -7.67M | -4.07M | -4.44M | -3.23M |
| EPS Basic | -0.36 | -0.44 | -0.18 | -0.26 | -0.19 |
| Normalized Basic EPS | -0.23 | -0.27 | -0.14 | -0.17 | -0.12 |
| EPS Diluted | -0.36 | -0.44 | -0.18 | -0.26 | -0.19 |
| Normalized Diluted EPS | -0.23 | -0.27 | -0.14 | -0.17 | -0.12 |
| Average Basic Shares Outstanding | 16.73M | 16.72M | 16.36M | 15.22M | 14.92M |
| Average Diluted Shares Outstanding | 16.73M | 16.72M | 16.36M | 15.22M | 14.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |